SENATE-BILL 1095: S.1095 - Stop STALLING Act
AI-Powered Summary
SENATE-BILL 1095 aims to enhance competition in the pharmaceutical market to lower drug prices and improve access to generic drugs and biosimilars, directly benefiting consumers who need affordable medication. The legislation addresses major themes of public health and consumer protection while raising constitutional concerns regarding due process and free speech. Key provisions include the establishment of civil penalties for individuals or entities submitting sham petitions that delay drug approvals, and the empowerment of the Federal Trade Commission to act against such submissions. The bill includes a severability clause to maintain its overall intent even if parts are deemed unconstitutional. Implementation will require the Federal Trade Commission to develop guidelines for enforcement, with a focus on balancing the need to deter frivolous petitions while protecting legitimate concerns. Potential impacts include increased access to medications and a more competitive market, but also raise questions about fairness in enforcement and the potential for executive overreach.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill aims to enhance access to essential medications by regulating the pharmaceutical industry, which has significant implications for individual rights, particularly for vulnerable populations. By reducing barriers to generic drug approval, it supports the right to access affordable healthcare, which is crucial for public welfare.
Key Individual Rights Affected
- Right to Access Healthcare
- Due Process Rights
- Equal Protection Under the Law
Constitutional Provisions
- Fifth Amendment (Due Process)
- Fourteenth Amendment (Equal Protection)
- Commerce Clause (regulatory authority)
Potential Constitutional Challenges Or Support
Challenges
- Due Process Concerns: The criteria for determining sham petitions may lack clarity, potentially leading to unfair penalties.
- Access to Justice: Smaller entities may struggle to contest civil actions, raising equity issues.
Support
- Public Health: The bill's focus on competition in the pharmaceutical market aligns with government interests in promoting public health.
- Regulatory Authority: It reinforces the FTC's role in ensuring fair competition, a recognized power under the Commerce Clause.
Summary
SENATE-BILL 1095 has the potential to significantly improve access to medications for individuals, particularly those in low-income brackets, seniors, and individuals with chronic health conditions. While it raises important due process and equal protection considerations, its overall intent to foster competition and lower drug prices aligns with constitutional principles aimed at promoting public health and welfare.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 1095 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
March 24, 2025
Bill Introduced
Current
Reported by Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat